BioCryst Pharmaceuticals Q4 2021 Earnings Preview

• BioCryst Pharmaceuticals (NASDAQ:BCRX) is scheduled to announce Q4 earnings results on Wednesday, February 23rd, before market open.
• The consensus EPS Estimate is -$0.29 (+14.7% Y/Y) and the consensus Revenue Estimate is $50.48M vs. $4M year ago.
• The company reported mixed results in Q3 with top line growth of 572% Y/Y
• Over the last 3 months, EPS estimates have seen 8 upward revisions and 1 downward. Revenue estimates have seen 8 upward revisions and 1 downward.